DAYLI Partners

DAYLI Partners is a specialized investment group focusing on the Bio·healthcare and Financial·fintech sectors. The firm is dedicated to creating sustainable value by leading industry evolution and innovation through investments grounded in unparalleled expertise and fervent execution.

Established in 2018, DAYLI Partners is based in Seoul, South Korea. The firm specializes in the bio-healthcare industry, discovering, building, and investing in next-generation life science companies, ranging from early to pre-IPO stages.

DAYLI Partners has made 97 investments, with notable exits including GI Innovation, Y-Biologics, and Curiox Biosystems. The firm's most recent investment was in Illimis Therapeutics on July 14, 2025. Notable portfolio companies include Curiox Biosystems, GenEdit, and Illimis Therapeutics.

The firm's investment strategy focuses on the biotechnology and healthcare sectors, with a particular emphasis on financial services and fintech. DAYLI Partners is committed to leading industry evolution and innovation through investments grounded in unparalleled expertise and fervent execution.

For more information, visit their official website at https://www.dayli.partners/en/ or contact them via email at contact@dayli.partners.

Please note that the information provided is based on available sources and may be subject to change. For the most current information, refer to the official website or contact the firm directly.